Volume 109, Issue 1, Pages 137–141.e2
Chantae Sullivan-Pyke, M.D., Daniel J. Haisenleder, Ph.D., Suneeta Senapati, M.D., M.S.C.E., Olivia Nicolais, B.A., Esther Eisenberg, M.D., M.P.H., Mary D. Sammel, Sc.D., Kurt T. Barnhart, M.D., M.S.C.E.
To validate the ability of serum kisspeptin-54 to discriminate between first-trimester viable pregnancies and miscarriages.
Academic medical centers.
Women with confirmed viable intrauterine pregnancy (IUP) at estimated gestational age 6–10 weeks (n = 20), women with confirmed miscarriage (spontaneous abortion [SAB]) at estimated gestational age 6–10 weeks (n = 20), and nonpregnant women (n = 19).
Collection of serum samples from women with confirmed IUP, SAB, and nonpregnant women for the measurement of serum kisspeptin and serum hCG levels.
Main Outcome Measure(s)
Serum kisspeptin and hCG.
The limit of detection was 0.024 ng/mL; intra- and interassay coefficients of variation were 5.1% and 8.6%, respectively. Kisspeptin levels differed between the pregnant and nonpregnant state and by viability. Kisspeptin levels were positively associated with gestational age. There was also a significant positive association with hCG in SAB, but not in IUP.
Plasma levels of kisspeptin have been suggested as a biomarker for miscarriage. This study demonstrates kisspeptin assay stability in serum and its potential clinical utility as a biomarker for early pregnancy viability.